Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Machackova, Eva ^a   Foretova, Lenka ^a   Lukesova, Mirka ^a   Vasickova, Petra ^a   Navratilova, Marie ^a   Coene, Ilse ^b   Pavlu, Hana ^a   Kosinova, Veronika ^a   Kuklova, Jitka ^a   Claes, Kathleen ^b  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; BRCA1 PROTEIN; BRCA2 PROTEIN; COMPLEMENTARY DNA; CYSTEINE; CYTOSINE; GLYCINE; GUANINE; MESSENGER RNA; TYROSINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GENETICS; CONTROLLED STUDY; CZECH REPUBLIC; FAMILY; FEMALE; GENE DELETION; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC CODE; GENETIC COUNSELING; GENETIC SCREENING; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OVARY CANCER; PATHOGENICITY; PROTEIN ANALYSIS; RNA SPLICING; BREAST TUMOR; GENETIC PREDISPOSITION; GENETICS; MUTATION; ONSET AGE; OVARY TUMOR; PATHOLOGY; RISK FACTOR;

AGE OF ONSET; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CZECH REPUBLIC; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MUTATION; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 44949263899     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-140     Document Type: Article

References (26)

1. Foretova L Petrakova K Palacova M Kalabova R Navratilova M Lukesova M Vasickova P Machackova E Kleibl Z Pohlreich P Genetic and preventive services for hereditary breast and ovarian cancer in the Czech Republic Hereditary Cancer in Clinical Practice 2006, 4:3-6.
2. Lux MP Fasching PA Beckmann MW Hereditary breast and ovarian cancer: review and future perspectives J Mol Med 2006, 84:16-28. 10.1007/ s00109-005-0696-7 16283147
3. Ford D Easton DF Narod S Goldgar D Devilee P Bishop DT Weber B Lenoir G Chang-Claude J Sobol H Teare MD Struewing J Arason A Scherneck S Peto J Rebbeck TR Tonin P Neuhausen S Barkardottir R Eyfjord J Lynch H Ponder BA Gayther SA Zelada-Hedman M Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium Am J Hum Genet 1998, 62:676-689. 1376944 9497246 10.1086/301749
4. Easton DF Ford D Bishop DT Breast Cancer Linkage Consortium Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium Am J Hum Genet 1995, 56(1):265-271. 7825587 1801337
5. Antoniou A Pharoah PD Narod S Rish HA Eyfjord JE Hopper JL Loman N Olsson H Johannsson O Borg A Pasini B Radice P Manoukian S Eccles DM Tang N Olah E Anton-Culver H Warner E Lubinski J Gronwald J Gorski B Tulinius H Thorlacius S Eerola H Nevanlinna H Syrjakoski K Kallopniemi OP Thompson D Evans C Peto J Lalloo F Evans DG Easton DF Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies Am J Hum Genet 2003, 72:1117-1130. 1180265 12677558 10.1086/375033
6. Narod SA Modifiers of risk of hereditary breast and ovarian cancer Nat Rev Cancer 2002, 2:113-123. 10.1038/nrc726 12635174
7. Friedman LS Ostermeyer EA Szabo CI Down P Lynch ED Rowel SE King MC Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families Nat Genet 1994, 8:399-404. 10.1038/ ng1294-399 7894493
8. Mazoyer S Dunning AM Serova O Dearden J Puget A Healey CS Gayther SA Mangion J Stratton MR Lynch HT Goldgar DE Ponder BAJ Lenoir GM A polymorphic stop codon in BRCA2 Nat Genet 1996, 14:253-254. 10.1038/ ng1196-253 8896551
9. Spain BH Larson CJ Shihabuddin LS Gage FH Verma IM Truncated BRCA2 is cytoplasmic: Implications for cancer-linked mutations Proc Natl Acad Sci USA 1999, 96:13920-13925. 24166 10570174 10.1073/pnas.96.24.13920
10. Hoffman JD Hallam SE Venne VL Lyon E Ward K Implications of a novel cryptic splice site in the BRCA1 gene Am J Med Genet 1998, 80:140-144. 10.1002/(SICI)1096-8628(19981102)80:2<140::AID-AJMG10>3.0.CO;2-L 9805131
11. Claes K Poppe B Machackova E Coene I Foretova L De Paepe A Messiaen L Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2 Genes Chromosomes Cancer 2003, 37:314-320. 10.1002/gcc.10221 12759930
12. Judkins T Hendricson BC Deffenbaugh AM Scholl T Single nucleotide polymorphisms in clinical genetic testing: The characterization of the clinical significance of genetic variants and their application in clinical research for BRCA1 Mutation Research 2005, 573:168-179. 15829246
13. Claes K Machackova E De Vos M Mortier G De Paepe A Messiaen L Mutation analysis of the BRCA1 and BRCA2 genes results in the identification of novel and recurrent mutations in 6/16 Flemish families with breast and/ or ovarian cancer but not in 12 sporadic patients with early-onset disease Hum Mutat 1999, 13:256. 10.1002/ (SICI)1098-1004(1999)13:3<256::AID-HUMU12>3.0.CO;2-M 10090482
14. Vasickova P Machackova E Lukesova M Damborsky J Horky O Pavlu H Kuklova J Kosinova V Navratilova M Foretova L High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic BMC Med Genet 2007, 8:32. 1904436 17561994 10.1186/1471-2350-8-32
15. O'Donovan MR Freemantle MR Hull G Bell DA Arlett CF Cole J Extended-term cultures of human T-lymphocytes: A practical alternative to primary human lymphocytes for use in genotoxicity testing Mutagenesis 1995, 10:189-201. 10.1093/mutage/10.3.189 7666770
16. Antonarakis SE the Nomenclature Working Group Recommendations for a nomenclature system for human gene mutations Hum Mutat 1998, 11:1-3. 10.1002/(SICI)1098-1004(1998)11:1<1::AID-HUMU1>3.0.CO;2-O 9450896
17. Meindl A German Consortium for Hereditary Breast and Ovarian Cancer Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population Int J Cancer 2002 97:472-480. 10.1002/ijc.1626 11802209
18. Claes K Poppe B Coene I Paepe AD Messiaen L BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families Br J Cancer 2004, 90:1244-51. 10.1038/sj.bjc.6601656 15026808
19. Brzovic PS Meza JE King MC Klevit RE BRCA1 RING domain cancer-predisposing mutations. Structural consequences and effects on protein-protein interactions J Biol Chem 2001, 276:41399-41406. 10.1074/ jbc.M106551200 11526114
20. Ruffner H Joazeiro CAP Hemmati D Hunter T Verma IM Cancer-predisposing mutations within the RING domain of BRCA1: Loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity PNAS 2001, 98:5134-5139. 33176 11320250 10.1073/pnas.081068398
21. Breast Cancer Information Core Database http://research.nhgri.nih.gov/ bic/
22. Gorski B Byrski T Huzarski T Lakubowska A Menkiszak J Gronwald J Pluzanska A Babenek M Fisher-Maliszewska L Grzybowska E Narod SA Lubinski J Founder mutations in the BRCA1 gene in Polish families with breast-ovarian Cancer Am J Hum Genet 2000, 66:1963-1968. 1378051 10788334 10.1086/302922
23. Reese MG Eeckman FH Kulp D Haussler D Improved splice site detection in Genie J Comput Biol 1997, 4:311-323. 9278062
24. Fang LJ Simard MJ Vidaud D Assouline B Lemieux B Vidaud M Chabot B Thirion JP A novel mutation in the neurofibromatosis type 1 (NF1) gene promotes skipping of two exons by preventing exon definition J Mol Biol 2001, 307:1261-70. 10.1006/jmbi.2001.4561 11292340
25. Thomassen M Kruse TA Jensen PK Gerdes AM A missense mutation in exon 13 in BRCA2, c.7235G>A, results in skipping of exon 13 Genet Test 2006, 10:116-120. 10.1089/gte.2006.10.116 16792514
26. Bieche I Lidereau R Somatic genetics of breast cancer Bull Cancer 1997, 84:83-96. 9180865